Physician profile
Pedram Taher
NPI 1669625125
$5,178.59
in general payments reported to CMS, 2019-2025
45 companies · $766 in 2025
The $766 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $595 · 2021: $492 · 2022: $878 · 2023: $608 · 2024: $834 · 2025: $766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,208.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,207.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,174.52 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $896.40 | 2021-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Pfizer INC. | $380.17 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $284.10 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $225.28 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $187.83 | 2019-2025 | Xifaxan |
| Amgen INC. | $182.45 | 2019-2025 | Krystexxa, Evenity |
| E.R. Squibb & Sons, L.L.C. | $143.72 | 2019-2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $135.94 | 2022-2024 | Austedo Xr, Uzedy |
| Revance Therapeutics, INC. | $110.85 | 2024 | Daxxify |
| Galderma Laboratories, L.P. | $102.35 | 2022 | |
| Glaxosmithkline, LLC. | $86.19 | 2023-2025 | Shingrix, Arexvy |
| Aimmune Therapeutics, INC. | $84.41 | 2025 | Zenpep |
| Sumitomo Pharma America, INC. | $76.04 | 2023-2024 | Gemtesa |
| Almatica Pharma LLC | $70.29 | 2023-2024 | Loreev Xr, Gralise |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pedram Taher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.